GHRH Analog Overview
CJC-1295 No DAC, also known as Modified GRF (1–29), is a synthetic growth hormone–releasing hormone (GHRH) analog engineered for advanced laboratory research. Its precisely defined amino acid sequence makes it suitable for controlled in vitro investigations of endocrine signaling mechanisms.
Structural Modifications & Stability
This peptide incorporates four targeted amino acid substitutions relative to native GRF sequences. These modifications are designed to improve resistance to enzymatic degradation, supporting enhanced stability during experimental workflows and prolonged assay conditions.
Mechanistic Research Applications
In research settings, Mod GRF 1–29 is utilized to study GHRH receptor interactions and downstream growth hormone release pathways. Its design allows researchers to explore receptor binding dynamics and signal amplification in cellular and biochemical models.
Manufacturing & Quality Standards
Produced in the United States under GMP-compliant, pharmaceutical-grade conditions, CJCND29 is manufactured with strict process controls. Each batch is independently analyzed by certified third-party laboratories to verify identity, purity, sterility, and endotoxin compliance.
Analytical Specifications
-
Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂
-
Molecular Formula: C152H252N44O42
-
Molecular Weight: 3367.954 g/mol
-
CAS Number: 863288-34-0
-
PubChem CID: 56841945
-
Synonyms: Mod GRF 1-29, CJC-1295 no DAC, Modified GRF (1-29), Tetrasubstituted GRF (1-29)
-
Purity: ≥99% (HPLC)
-
Form: White lyophilized powder
-
Solubility: Soluble in bacteriostatic water
-
Storage: ≤4°C, sealed, protected from heat and moisture
-
Shelf Life: 36 months under recommended storage conditions
Research-Only Classification
CJCND29 is supplied exclusively for in vitro research use (RUO). It is not intended for human or animal consumption, clinical use, diagnostic procedures, or therapeutic development.
